Case report: first-line lorlatinib in metastatic lung adenocarcinoma with a novel WIPF1-ALK and EML4-ALK dual fusion
{{output}}
Background: The clinical management of non-small cell lung cancer (NSCLC) harboring rare anaplastic lymphoma kinase (ALK) fusion variants and complex molecular profiles remains challenging. Herein, we report, for the first time, ... ...
